2011年-普华永道全球_Pharma_2020_Supplying_the_future_36页_1mb

Pharma 2020: Supplying the Future – Summary

Core Content

This document outlines the major changes and challenges that the pharmaceutical industry will face by 2020, focusing on the transformation of the supply chain. It emphasizes the need for a radical reconfiguration of traditional supply chain models to meet the evolving demands of the market, driven by new product types, regulatory changes, environmental pressures, and the rise of emerging markets.

Main Trends and Challenges

• New Product Types: The industry is moving towards a more diverse range of products, including bioengineered vaccines, biologics, and personalized medicines. These require more complex manufacturing and distribution processes.
• Live Licensing: Regulatory frameworks are evolving to allow for conditional approvals and phased launches, which will change how companies manage their supply chains to support incremental revenue growth.
• Emphasis on Outcomes: Governments and insurers are demanding evidence of the effectiveness of medicines. Pharma must shift from a product-centric model to one that integrates services and data to deliver value.
• New Healthcare Delivery Models: There is a trend towards community-based care, self-administration, and the use of digital tools such as e-prescribing and electronic health records. This requires more flexible and demand-driven supply chains.
• Growing Importance of Emerging Markets: These markets are becoming more critical, but they present unique challenges such as higher patient out-of-pocket costs, different consumer values, and increased risks of counterfeit medicines.
• Greater Public Scrutiny: Regulatory agencies are becoming more rigorous in their oversight, leading to a higher emphasis on risk management and compliance across the supply chain.
• Environmental Pressures: The industry must adapt to stricter environmental regulations and resource scarcity, particularly concerning water and energy. This includes the need for more sustainable and eco-friendly manufacturing processes.

Key Business Models and Strategies

Pharma companies are presented with four potential supply chain strategies:

1. Virtual Manufacturer: Utilizing digital tools and virtual process design to streamline manufacturing and reduce costs.
2. Service Innovator: Building service-oriented supply chains that provide additional value through patient support services.
3. Low-Cost Provider: Focusing on cost-effective manufacturing and distribution, especially for mass-market medicines.
4. Profit Centre: Developing supply chains that generate profit by serving both internal and external customers.

Technologies Enabling Change

• New Development Technologies: Advanced drug delivery methods and the potential for oral biologics.
• Virtual Process Design and Validation: Using computational modeling and Quality by Design (QbD) to simulate and validate manufacturing processes.
• New Manufacturing Technologies: Continuous processing, automation, and micro-reactor systems that improve efficiency and reduce costs.
• New Distribution Technologies: More efficient 'final mile' delivery systems and demand-driven supply chains.
• Collaboration: Emphasizing the importance of partnerships across the industry, including with researchers, governments, and healthcare providers.

Implications for the Industry

• The traditional supply chain model is no longer sufficient.
• Pharma companies must invest in more flexible, efficient, and sustainable processes.
• Supply chains will need to adapt to new product types and delivery models, and will be more integrated with patient data and services.
• Companies must be prepared to restructure their asset bases and re-engineer manufacturing facilities to meet future demands.

Conclusion

The pharmaceutical industry is at a crossroads, facing a need to transform its supply chain to align with new market realities. This transformation is driven by technological advancements, regulatory changes, and evolving patient and healthcare provider expectations. Companies that can adapt to these changes and choose the right supply chain strategy will be better positioned to succeed in the future.